Icon

VIVIMUSTA (nda212209)- (100MG/4ML (25MG/ML))

BENDAMUSTINE HYDROCHLORIDE AZURITY
100MG/4ML (25MG/ML)
No Yes
2042-Jul-29 Expired
None None
None No
VIVIMUSTA is an alkylating drug indicated for treatment of patients with: • Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
0 0 0
Total Other Developers 1
Drugs with Suitability No
100MG/4ML (25MG/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.